Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment
暂无分享,去创建一个
[1] Claude Preudhomme,et al. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. , 2003, Seminars in hematology.
[2] Krishnendu Chatterjee,et al. Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.
[3] W P Lee,et al. The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine. , 1993, Cancer letters.
[4] Mina J Bissell,et al. The tumor microenvironment is a dominant force in multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[5] B. Frieden,et al. Adaptive therapy. , 2009, Cancer research.
[6] Fei Li,et al. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients , 2015, PloS one.
[7] D. T. Birtwistle. Introduction to Mathematical Control Theory , 1976 .
[8] Vittorio Cristini,et al. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology , 2014, Current Breast Cancer Reports.
[9] M. Gottesman,et al. The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .
[10] H. Ohdan,et al. Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma , 2016, Cancer medicine.
[11] Alexander Lorz,et al. Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. , 2015, Cancer research.
[12] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[13] J H Goldie,et al. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.
[14] Franziska Michor,et al. Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia , 2011, PloS one.
[15] K. Borden,et al. Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..
[16] R. Wood,et al. DNA polymerases and cancer , 2011, Nature Reviews Cancer.
[17] S. Menchón. The Effect of Intrinsic and Acquired Resistances on Chemotherapy Effectiveness , 2015, Acta Biotheoretica.
[18] Mahmood Rasool,et al. Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era , 2013, PloS one.
[19] Zahra Aminzare,et al. Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model , 2014, 1412.0780.
[20] W. Pao,et al. Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2011, Molecular pharmaceutics.
[21] Shannon M. Mumenthaler,et al. Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors , 2012, Evolutionary applications.
[22] D. Waxman,et al. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. , 2015, Cancer letters.
[23] J. Turchi,et al. Chemotherapy induced DNA damage response , 2013, Cancer biology & therapy.
[24] P. Majumder,et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.
[25] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] W. Lu,et al. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model , 2013, Acta Pharmacologica Sinica.
[27] Krutiakov Vm. [Eukaryotic error prone DNA polymerases: suggested roles in replication, repair and mutagenesis]. , 2006 .
[28] Joel s. Brown,et al. Evolutionary dynamics in cancer therapy. , 2011, Molecular pharmaceutics.
[29] Mitra Shojania Feizabadi. Modeling multi-mutation and drug resistance: analysis of some case studies , 2017, Theoretical Biology and Medical Modelling.
[30] Cécile Carrère,et al. Optimization of an in vitro chemotherapy to avoid resistant tumours. , 2017, Journal of theoretical biology.
[31] C. Blank,et al. Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.
[32] B. Chauffert,et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.
[33] Richard F. Kefford,et al. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.
[34] N. Makridakis,et al. Translesion DNA Polymerases and Cancer , 2012, Front. Gene..
[35] R. Golsteyn,et al. Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells , 2014, International journal of molecular sciences.
[36] Robert A Gatenby,et al. Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy , 2012, Physical biology.
[37] H M Byrne,et al. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. , 2000, Mathematical biosciences.
[38] Robert A Gatenby,et al. A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.
[39] Martin A. Nowak,et al. Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy , 2014, PLoS Comput. Biol..
[40] F. Michor,et al. Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.
[41] Gábor E. Tusnády,et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.
[42] K. Hirota,et al. Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers , 2014, PloS one.
[43] S. Wong,et al. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[44] Martin A. Nowak,et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity , 2015, Nature.
[45] Gerald J. Fetterly,et al. Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia , 2013, The AAPS Journal.
[46] Katarzyna A Rejniak,et al. Limiting the Development of Anti-Cancer Drug Resistance in a Spatial Model of Micrometastases , 2016, bioRxiv.
[47] Aleksandra Karolak,et al. Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance. , 2016, Advances in experimental medicine and biology.
[48] Amy Brock,et al. Non-Darwinian dynamics in therapy-induced cancer drug resistance , 2013, Nature Communications.
[49] Joseph M. Negri,et al. The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.
[50] P. Langenberg,et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Roberto Chignola,et al. Estimating the growth kinetics of experimental tumors from as few as two determinations of tumor size: implications for clinical oncology , 2005, IEEE Transactions on Biomedical Engineering.
[52] F. Michor,et al. Evolution of resistance to anti-cancer therapy during general dosing schedules. , 2010, Journal of theoretical biology.
[53] Anna Sótér,et al. Two-photon laser spectroscopy of antiprotonic helium and the antiproton-to-electron mass ratio , 2011, Nature.
[54] M. Nowak,et al. Evolution of resistance to cancer therapy. , 2006, Current pharmaceutical design.
[55] V. Krutyakov. Eukaryotic error-prone DNA polymerases: The presumed roles in replication, repair, and mutagenesis , 2006, Molecular Biology.
[56] Sarah A Heerboth,et al. Drug Resistance in Cancer: An Overview , 2014, Cancers.
[57] Franziska Michor,et al. Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..
[58] B. Perthame,et al. Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies , 2012, 1207.0923.
[59] S. Shackney,et al. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. , 1978, Annals of internal medicine.
[60] B. Perthame,et al. Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.
[61] Doron Levy,et al. The dynamics of drug resistance: a mathematical perspective. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[62] H. Coley,et al. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[63] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[64] Lurias,et al. MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .
[65] Robert A. Gatenby,et al. Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.
[66] William Pao,et al. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells , 2015, Cancer informatics.
[67] Martin A Nowak,et al. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers , 2014, Proceedings of the National Academy of Sciences.
[68] Nicolas André,et al. Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.
[69] M. Gottesman,et al. The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.
[70] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[71] A. Pisco,et al. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.
[72] Sydney M. Shaffer,et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.
[73] Georgios D. Mitsis,et al. Mathematical Modeling of Tumor Growth, Drug-Resistance, Toxicity, and Optimal Therapy Design , 2014, IEEE Transactions on Biomedical Engineering.
[74] I. Tannock,et al. Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.
[75] Claire J. Tomlin,et al. A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations , 2016, 2016 IEEE 55th Conference on Decision and Control (CDC).
[76] Franziska Michor,et al. Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. , 2017, Cancer research.
[77] J. Nyce,et al. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. , 1997, Mutation research.
[78] D. Axelrod,et al. Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study , 2017, Cancer Chemotherapy and Pharmacology.
[79] Y. Erdi. Limits of Tumor Detectability in Nuclear Medicine and PET , 2012, Molecular imaging and radionuclide therapy.
[80] Urszula Ledzewicz,et al. Drug resistance in cancer chemotherapy as an optimal control problem , 2005 .
[81] Eduardo D. Sontag. Dynamic compensation, parameter identifiability, and equivariances , 2017, PLoS Comput. Biol..
[82] Lena E Friberg,et al. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response , 2013, British journal of clinical pharmacology.
[83] Christopher P Austin,et al. A dual-fluorescence high-throughput cell line system for probing multidrug resistance. , 2009, Assay and drug development technologies.
[84] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[85] Dominik Wodarz,et al. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. , 2007, Theoretical population biology.
[86] Larry Norton,et al. Log-Kill Hypothesis , 2015 .
[87] L. Loeb,et al. Errors in DNA replication as a basis of malignant changes. , 1974, Cancer research.
[88] Urszula Ledzewicz,et al. A 3-Compartment Model for Chemotherapy of Heterogeneous Tumor Populations , 2015 .
[89] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.